These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31789670)

  • 1. Dietary fructose and dyslipidemia: new mechanisms involving apolipoprotein CIII.
    Hieronimus B; Stanhope KL
    Curr Opin Lipidol; 2020 Feb; 31(1):20-26. PubMed ID: 31789670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Fructose or Glucose on Circulating ApoCIII and Triglyceride and Cholesterol Content of Lipoprotein Subfractions in Humans.
    Hieronimus B; Griffen SC; Keim NL; Bremer AA; Berglund L; Nakajima K; Havel PJ; Stanhope KL
    J Clin Med; 2019 Jun; 8(7):. PubMed ID: 31247940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
    Rocha NA; East C; Zhang J; McCullough PA
    Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein CIII and diabetes. Is there a link?
    Christopoulou E; Tsimihodimos V; Filippatos T; Elisaf M
    Diabetes Metab Res Rev; 2019 Mar; 35(3):e3118. PubMed ID: 30557902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia.
    Caron S; Verrijken A; Mertens I; Samanez CH; Mautino G; Haas JT; Duran-Sandoval D; Prawitt J; Francque S; Vallez E; Muhr-Tailleux A; Berard I; Kuipers F; Kuivenhoven JA; Biddinger SB; Taskinen MR; Van Gaal L; Staels B
    Arterioscler Thromb Vasc Biol; 2011 Mar; 31(3):513-9. PubMed ID: 21183731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Apolipoprotein CIII trials.
    Tramontano D; Bini S; D'Erasmo L; Arca M
    Curr Opin Lipidol; 2022 Dec; 33(6):309-318. PubMed ID: 36206093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein CIII links dyslipidemia with atherosclerosis.
    Kawakami A; Yoshida M
    J Atheroscler Thromb; 2009 Mar; 16(1):6-11. PubMed ID: 19262004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease.
    Zheng C
    Curr Opin Lipidol; 2014 Feb; 25(1):35-9. PubMed ID: 24345989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study.
    Katzmann JL; Werner CM; Stojakovic T; März W; Scharnagl H; Laufs U
    Lipids Health Dis; 2020 May; 19(1):116. PubMed ID: 32473635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins.
    Mendivil CO; Zheng C; Furtado J; Lel J; Sacks FM
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):239-45. PubMed ID: 19910636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia.
    Kypreos KE
    Biochemistry; 2008 Sep; 47(39):10491-502. PubMed ID: 18767813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dietary saturated fat on LDL subclasses and apolipoprotein CIII in men.
    Faghihnia N; Mangravite LM; Chiu S; Bergeron N; Krauss RM
    Eur J Clin Nutr; 2012 Nov; 66(11):1229-33. PubMed ID: 22948944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein CIII is a new player in diabetes.
    Juntti-Berggren L; Berggren PO
    Curr Opin Lipidol; 2017 Feb; 28(1):27-31. PubMed ID: 27875339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen.
    Zhang J; Rocha NA; McCullough PA
    Rev Cardiovasc Med; 2018 Mar; 19(1):13-19. PubMed ID: 31032598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction.
    Kawakami A; Osaka M; Tani M; Azuma H; Sacks FM; Shimokado K; Yoshida M
    Circulation; 2008 Aug; 118(7):731-42. PubMed ID: 18663085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein CIII bound to apoB-containing lipoproteins is associated with small, dense LDL independent of plasma triglyceride levels in healthy men.
    Shin MJ; Krauss RM
    Atherosclerosis; 2010 Jul; 211(1):337-41. PubMed ID: 20303494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.
    Ebara T; Ramakrishnan R; Steiner G; Shachter NS
    J Clin Invest; 1997 Jun; 99(11):2672-81. PubMed ID: 9169497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ApoCIII: A multifaceted protein in cardiometabolic disease.
    D'Erasmo L; Di Costanzo A; Gallo A; Bruckert E; Arca M
    Metabolism; 2020 Dec; 113():154395. PubMed ID: 33058850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells.
    Kawakami A; Aikawa M; Libby P; Alcaide P; Luscinskas FW; Sacks FM
    Circulation; 2006 Feb; 113(5):691-700. PubMed ID: 16461842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
    Morton AM; Furtado JD; Lee J; Amerine W; Davidson MH; Sacks FM
    J Clin Lipidol; 2016; 10(6):1442-1451.e4. PubMed ID: 27919362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.